• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

CIDRAP- UNICEF appeal targets rising mpox cases in African kids

Lance

MPH, CSP & CIT Retired, CHMM Emeritus
https://www.cidrap.umn.edu/mpox/unicef-appeal-targets-rising-mpox-cases-african-kids

UNICEF appeal targets rising mpox cases in African kids



Lisa Schnirring


Today at 4:24 p.m.

Mpox
UNICEF yesterday announced the launch of a $58.8 million appeal to support the mpox response in six African countries where children are most affected by the disease.

In other developments, the United Kingdom detailed its response plan, including buying more vaccine, and US officials spelled out a research agenda for the virus, including exploring ways to maximize vaccine doses.

Kids make up more than half of cases in some African nations


The focus of UNICEF’s appeal are children in Burundi, the Democratic Republic of the Congo (DRC), Kenya, Rwanda, Uganda, and the Central African Republic, all of which are experiencing rising clade 1 mpox activity.

UNICEF said 60% of the nearly 22,000 suspected and confirmed mpox cases in Africa this year are in children younger than 15 years old and that 80% of the more than 700 mpox deaths have involved kids. So far, the DRC is the only country to report fatal infections in children.

UK shores up vaccine supply, shares response plan


In developments outside of Africa, the United Kingdom's government yesterday announced that it has ordered 150,000 more Bavarian Nordic mpox vaccine doses to help the country prepare for any clade 1 cases that are detected in the country.

So far two clade 1 cases have recently been found outside of Africa, one in Sweden and the other in Thailand. Global health officials, however, are on high alert for imported cases in people who have traveled to outbreak countries.

In a statement yesterday, the government said it is at the forefront of the international response and has provided critical support to the DRC. Wes Sterling, the UK’s secretary of state for social care, said, "No cases of clade 1 mpox have been detected in the UK, but we are taking steps to ensure the country is prepared with a robust vaccination programme that protects those who may be at high risk."

Risk groups targeted for vaccination include men who have sex with men, certain healthcare workers, health and humanitarian workers traveling to affected countries, and close contacts of confirmed cases.

In a related development, the UK Health Security Agency (HSA) recently posted a technical briefing on mpox, which spelled out possible scenarios for a clade 1b mpox outbreak in the country, ranging from incursions and small clusters to community transmission.

It also laid out risk levels, noting that it currently considers the risk of importation as low to medium. The HSA also detailed its border response options, some of which are already in effect.

NIH unveils mpox research agenda


The US National Institutes of Health (NIH) today unveiled the National Institute of Allergy and Infectious Diseases (NIAID) mpox research agenda, which focuses on four main areas. They include understanding the biology of all clades including how the virus is transmits and how the immune system responds, how to stretch the vaccine supply, advancing treatments, and improving diagnostics.
 
Back
Top Bottom